• Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting
  • Data to be presented at an upcoming medical meeting and shared with global regulatory authorities